FDA budget mark-up
This article was originally published in The Gray Sheet
Agency's fiscal year 1999 budget will be marked up by the Senate Appropriations/Agriculture Subcommittee June 9 and by the House Appropriations/Agriculture Subcommitee on June 10. FDA's proposed budget, which calls for flat funding compared to FY 1998 for the Center for Devices and Radiological Health, was reviewed by the House Subcommittee Feb. 25 ("The Gray Sheet" March 2, p. 10) and the Senate March 31 ("The Gray Sheet" April 6, p. 5)...
You may also be interested in...
China's centralized procurement scheme, if further expanded after causing the prices of 32 drugs to be cut by more than half in the latest round, will leave companies no room to breathe easy amid the already devastating coronavirus outbreak, analysts say.
Sangamo licensed Biogen zinc finger protein transcription factor candidates in an alliance worth over $2bn. Exercising an option it gained in 2017, Takeda bought celiac disease-focused PvP Biologics for up to $330m in earn-outs. A strong showing of IPOs prompted biopharma financing to increase from last month.
With many non-CE marked products being allowed onto various EU member state markets, who is going to monitor compliance? TÜV-SÜD’s Bassil Akra calls for cooperation to avoid unsafe products being used on patients.